Center for Cellular Immunotherapies logo` Center for Cellular Immunotherapies

Binder Lab

Publications

  1. Singh N, Orlando E, Xu J, Xu J, Binder Z, Collins MA, O'Rourke DM, Melenhorst JJ. Mechanisms of resistance to CAR T cell therapies. Semin Cancer Biol, 2020 Oct;65:91-98. doi: 10.1016/j.semcancer.2019.12.002. Epub 2019 Dec 19. Review. PubMed PMID: 31866478.
  2. Nabavizadeh SA, Ware JB, Guiry S, Nasrallah MP, Mays JJ, Till JE, Hussain J, Abdalla A, Yee SS, Binder ZA, O’Rourke DM, Brem S, Desai AS, Wolf R, Carpenter EL, Bagley SJ. Imaging and histopathologic correlates of plasma cell-free DNA concentration and circulating tumor DNA in adult patients with newly diagnosed glioblastoma. Neuro-Oncology Advances, Volume 2, Issue 1, January-December 2020, vdaa016, https://doi.org/10.1093/noajnl/vdaa016
  3. Huang M, Zhang D, Wu JY, Xing K, Yeo E, Li C, Zhang L, Holland E, Yao L, Qin L, Binder ZA, O’Rourke DM, Brem S, Koumenis C, Gong Y, Fan Y. Wnt-mediated endothelial transformation into mesenchymal stem cell–like cells induces chemoresistance in glioblastoma. Science Translational Medicine 26 Feb 2020: Vol. 12, Issue 532, eaay7522 DOI: 10.1126/scitranslmed.aay7522
  4. Struve N, Binder ZA, Stead LF, Brend T, Bagley SJ, Faulkner C, Ott L, Müller-Goebel J, Weik AS, Hoffer K, Krug L, Rieckmann T, Bußmann L, Henze M, Morrissette JJD, Kurian KM, Schüller U, Petersen C, Rothkamm K, O Rourke DM, Short SC, Kriegs M. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma. Oncogene. 2020 Feb 17. doi: 10.1038/s41388-020-1208-5. [Epub ahead of print]
  5. Bagley SJ, Nabavizadeh SA, Mays JJ, Till JE, Ware JB, Levy S, Sarchiapone W, Hussain J, Prior T, Guiry S, Christensen T, Yee SS, Nasrallah MP, Morrissette JJD, Binder ZA, O'Rourke DM, Cucchiara AJ, Brem S, Desai AS, Carpenter EL. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. Clin Cancer Res. 2020 Jan 15;26(2):397-407. doi: 10.1158/1078-0432.CCR-19-2533. Epub 2019 Oct 30.
  6. Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, Thokala R, Sheikh S, Saxena D, Prokop S, Liu DA, Qian X, Petrov D, Lucas T, Chen HI, Dorsey JF, Christian KM, Binder ZA, Nasrallah M, Brem S, O'Rourke DM, Ming GL, Song H. A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell. 2020 Jan 9;180(1):188-204.e22. doi: 10.1016/j.cell.2019.11.036. Epub 2019 Dec 26.
  7. Saxena D, Sheikh S, Kao G, Binder ZA, Alonso-Basanta M, O'Rourke DM, Nasrallah MP, Dorsey JF. Rapid and ultrasensitive digital PCR (dPCR) profiling of EGFRvIII in tumor cells and tissues. Neurooncol Adv. 2019 May-Dec;1(1):vdz030. doi: 10.1093/noajnl/vdz030. Epub 2019 Nov 28. PubMed PMID: 31807732; PubMed Central PMCID: PMC6881905.
  8. Nasrallah MP, Binder ZA, Oldridge DA, Zhao J, Lieberman DB, Roth JJ, Watt CD, Sukhadia S, Klinman E, O’Rourke DM, Morrissette JJD. Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma.  Acad Pathol, 2019 May 27. doi.org/10.1177/2374289519848353
  9. Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, Cook DR, Thokala R, Blouch K, McGettigan-Croce B, Konradt C, Zhang L, Cogdill AP, Panjwani MK, Jiang S, Migliorini D, Dahmane N, Posey AD, June CH, Mason NJ, Lin Z, Johnson LA, O’Rourke DM. Checkpoint blockade reverse anergy in IL13Rα2 humanizedscFv based chimeric antigen receptor-T cells to treat glioma in mice. Molecular Therapy-Oncolytics. 2018 Aug 28;11:20-38. doi: 10.1016/j.omto.2018.08.002.
  10. Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Orellana L, Scott AM, Davatzikos C, Furnari FB, O’Rourke DM. Epidermal Growth Factor Receptor extracellular domain mutations in glioblastoma present opportunities for clinical imaging and therapeutic development. Cancer Cell. 2018 Jul 9;34(1):163-177.e7. doi: 10.1016/j.ccell.2018.06.006.
  11. Rathore S, Akbari H, Rozycki M, Abdullah K, Nasrallah M, Binder ZA, Davuluri RV, Lustig RA, Dahmane N, Bilello M, O’Rourke DM, Davatzikos C. Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1. Sci Rep. 2018 Mar 23;8(1):5087.

Back to top